ClinicalTrials.gg
CompletedNCT02571816Updated Nov 5, 2024

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215

A Phase 1 interventional study of ASP2215 in Hepatic Impairment and Healthy, sponsored by Astellas Pharma Global Development, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to compare the single-dose pharmacokinetics of ASP2215 in subjects with mild and moderate hepatic impairment to matched healthy subjects with normal hepatic function.

This study will also assess the safety and tolerability of single-dose ASP2215 in subjects with mild and moderate hepatic impairment and matched control subjects.

Read the detailed description

Subjects will be admitted to the site one day before each study drug administration (i.e. Day -1) and confined at the site till the collection of post-dose PK samples (Day 21). For subjects with hepatic impairment, subject will discharge on Day 21, and will visit the clinical unit on Day 24 (±1 day) and Day 28 (±1 day) for collection of post-dose PK samples. End of study Visit For Healthy subjects will take place 1 to 5 days following collection of last PK sample.

02

Conditions studied

  • Hepatic Impairment
  • Healthy

Keywords

  • Hepatic Impairment
  • Mild Hepatic Impairment
  • Healthy
  • ASP2215
  • Moderate Hepatic Impairment
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A prospective subject is eligible for the clinical study if all of the following apply:

  • Subject has a (BMI) range of 18.5 - 34.0 kg/m2, inclusive and weighs at least 50 kg at screening.
  • Female subject must be nonchildbearing potential;

    • (defined as at least 1 year without any menses) prior to screening, or
    • Documented surgically sterile (at least 1 month prior to screening), and
    • Female subject must have a negative pregnancy test at screening and Day -1.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 45 days after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period and for 45 days after the final study drug administration.
  • Male subject and their female spouse/partners who are of must be using 2 forms of highly effective (1 of which must be a barrier method) starting at screening and continue throughout the study period and for 105 days after the final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the study period and for 105 days after the final study drug administration.
  • Subject agrees not to participate in another interventional study while participating in the present study, defined as signing the form until completion of the last study visit.

In addition, subjects with mild or moderate hepatic impairment must also meet the following inclusion criterion:

  • Subject must have a classification Class A (mild, 5 to 6 points) or Class B (moderate, 7 to 9 points) liver function impairment at screening.

Exclusion criteria

Exclusion Criteria:

A prospective subject will be excluded from participation in this clinical study if any of the following apply:

  • Female subject who has been pregnant within 6 months prior to screening assessment or breastfeeding within 3 months prior to screening.
  • Subject has a known or suspected to ASP2215, or any components of the formulation used.
  • Subject has any history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies prior to study drug administration).
  • Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to day -1.
  • Subject has a long (QTc) at baseline
  • Subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or long corrected QT interval (QTc) syndrome or family history of long QTc syndrome
  • Subjects with hypokalemia and hypomagnesemia at screening (defined as values below lower limit of normal).
  • Subject has a mean pulse \< 40 or > 90 bpm; mean systolic blood pressure (SBP) >160 mmHg; mean diastolic blood pressure (DBP) >100 mmHg (measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically) at day -1. If the mean blood pressure exceeds the limits above, 1 additional triplicate can be taken.
  • Subject who has received the following drugs/products within 2 weeks prior to dosing:

    • Strong or moderate inhibitors (e.g., ketoconazole or fluconazole) or inducers (e.g., rifampin or phenytoin) of cytochrome P450 (CYP)3A4
    • Inhibitors and inducers of P-glycoprotein (P-gp)
    • Substrates of multidrug and toxin extrusion (MATE) 1
    • Drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5 hydroxytryptamine receptor 2B (5HT2BR)
  • Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.
  • Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor) or the subject tests positive for alcohol or drugs of abuse at screening or day -1 (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates).
  • Subject has used any drugs of abuse within 3 months prior to admission to the clinical unit.
  • Subject anticipates an inability to abstain from xanthine (e.g., caffeine), grapefruit, Seville oranges (including marmalade), star fruit or any products containing these items from 72 hours prior to day -1 and throughout the duration of the study.
  • Subject has significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to day -1.
  • Subject has participated in any clinical study or has been treated with any drugs within 30 days or 5 half-lives, whichever is longer, prior to screening.
  • Subject has any condition which, in the investigator's opinion, makes the subject unsuitable for study participation.
  • Subject is an employee of the Astellas Group or Contract Research Organization.

In addition, healthy subjects must also NOT meet the following exclusion criteria:

  • Subject used any prescribed or nonprescribed drugs (including vitamins, oral or hormone replacement therapy, natural and herbal remedies, e.g., St. John's Wort) in the 2 weeks prior to study drug administration, except for occasional use of acetaminophen (up to 2 g per day).
  • Subject has any clinically significant abnormality following the investigator's review of the physical examination, and protocol defined clinical laboratory tests at screening or day -1.
  • Subject uses any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit.
  • Subject has a positive serology test for surface antigen, hepatitis A virus antibodies (immunoglobulin M), virus antibodies, hepatitis B core antibody or type 1 or 2 at screening.
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or , as judged by the investigator.
  • Subject has any of the liver chemistry tests (, alanine aminotransferase, alkaline phosphatase and total ) above the at day -1. If the test is outside the reference range, the test may be repeated once.

In addition, subjects with mild or moderate hepatic impairment must also NOT meet the following exclusion criteria:

  • Subject has any clinically significant abnormality, not related to their current disease state, following the investigator's review of the physical examination, ECG and protocol defined clinical laboratory tests at screening or day -1.
  • Subject has a fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period (e.g., worsening ascites, infection of ascites, fever, active gastrointestinal bleeding).
  • Subject has had a change in dose regimen of medically required medication within the last 2 weeks before prestudy examination (allowed co medication in patients), and/or the use of unallowed co medication in the 3 weeks prior to admission to the clinical unit (not allowed: any known hepatic enzyme altering agents or compounds known to restrict metabolism).
  • Subject has presence of a hepatocellular carcinoma or an acute liver disease caused by an infection or drug toxicity.
  • Subject has severe portal hypertension or surgical porto-systemic shunts, including Transjugular intrahepatic portosystemic shunt (TIPSS).
  • Subject has biliary liver cirrhosis, biliary obstruction or other cause of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
  • Subject has signs of significant hepatic encephalopathy (hepatic encephalopathy grade >2).
  • Subject has severe ascites and/or pleural effusion.
  • Subject had esophageal/gastric variceal bleeding in the past 6 months prior to screening.
  • Subject has a level below 40 × 109 /L and/or below 90 g/L.
  • Subject had a previous liver transplantation.
  • Subject has severe or moderate renal dysfunction (estimated [eGFR] below 60 mL/min/1.73m2) estimated via the following Modification of Diet in Renal Disease (MDRD) equation: eGFR (mL/min/1.73 m2) = 175 × (SCr [mg/dL]) -1.154 × (Age) -0.203 × (0.742 if female) × (1.212 if black)
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ASP2215: Subjects with mild hepatic impairment

    Subjects with Child Pugh classification score of 5-6 (mild)

    Drug: ASP2215

  • Experimental
    ASP2215: Subjects with moderate hepatic impairment

    Subjects with Child Pugh classification score of 7-9 (moderate)

    Drug: ASP2215

  • Experimental
    ASP2215: Subjects with normal hepatic function

    Healthy subjects that match with respect to age, sex and body mass index (BMI)

    Drug: ASP2215

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of ASP2215 in plasma: AUCinf

    Area under the curve from time zero to infinity (AUCinf)

    Time frame: Up to Day 28

  2. Pharmacokinetics of ASP2215 in plasma: AUClast, 480

    Area under the concentration-time curve from the time of dosing to the last measurable concentration within 480 hours postdose (AUClast,480)

    Time frame: Up to Day 28

  3. Pharmacokinetics of ASP2215 in plasma: Cmax

    Maximum concentration (Cmax)

    Time frame: Up to Day 28

Secondary outcomes

  1. Pharmacokinetics of ASP2215 in plasma: t1/2

    Apparent Terminal Elimination Half-life (t1/2)

    Time frame: Up to Day 28

  2. Pharmacokinetics of ASP2215 in plasma: tmax

    The time after dosing when Cmax occurs (tmax)

    Time frame: Up to Day 28

  3. Pharmacokinetics of ASP2215 in plasma: CL/F

    Apparent total systemic clearance after extravascular dosing (CL/F)

    Time frame: Up to Day 28

  4. Pharmacokinetics of ASP2215 in plasma: Vz/F

    Apparent volume of distribution during the terminal elimination phase after single extravascular dosing (Vz/F)

    Time frame: Up to Day 28

  5. Pharmacokinetics of ASP2215 in plasma: fu

    Fraction of parent or metabolite available systemically unbound (=free fraction) (fu)

    Time frame: Up to Day 28

  6. Pharmacokinetics of ASP2215 in plasma: AUClast

    Area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)

    Time frame: Up to Day 28

  7. Pharmacokinetics of ASP2215 in plasma: AUClast,u

    Area under the concentration-time curve from the time of dosing to the last measurable concentration for unbound concentration (AUClast,u)

    Time frame: Up to Day 28

  8. Pharmacokinetics of ASP2215 in plasma: AUCinf,u

    Area under the concentration-time curve from the time of dosing extrapolated to time infinity for unbound concentration (AUCinf,u)

    Time frame: Up to Day 28

  9. Pharmacokinetics of ASP2215 in plasma: AUClast,480,u

    Area under the concentration-time curve from the time of dosing to the last measurable concentration within 480 postdose for unbound concentration (AUClast,480,u)

    Time frame: Up to Day 28

  10. Pharmacokinetics of ASP2215 in plasma: Cmax,u

    Maximum concentration for unbound concentration (Cmax,u)

    Time frame: Up to Day 28

  11. Pharmacokinetics of ASP2215 in plasma: CLu/F

    Apparent total systemic clearance of unbound ASP2215 after extravascular dosing (CLu//F)

    Time frame: Up to Day 28

  12. Pharmacokinetics of ASP2215 in plasma: Vz,u/F

    Apparent volume of distribution during the terminal elimination phase of unbound ASP2215 after extravascular dosing (Vz,u/F)

    Time frame: Up to Day 28

  13. Safety profile assessed by Adverse Events (AEs), Clinical laboratory evaluations, 12-Lead electrocardiogram (ECG) and Vital signs

    Clinical laboratory evaluations include hematology, biochemistry, and urinalysis. Vital signs include oral temperature, respiration rate, pulse, and supine blood pressure.

    Time frame: Up to Day 34

07

Study locations

1 site
  • Site US10001
    Miami, Florida 33014, United States
08

References and documents

Publications

  • James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2020 Oct;59(10):1273-1290. doi: 10.1007/s40262-020-00888-w. Erratum In: Clin Pharmacokinet. 2021 Sep;60(9):1251. doi: 10.1007/s40262-021-01060-8. PubMed 32304015 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Mar 2016, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2015
First posted
Oct 8, 2015
StartActual
Oct 23, 2015
Primary completionActual
Mar 5, 2016
CompletionActual
Mar 5, 2016
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02571816
Responsible party
Sponsor
First posted
Oct 8, 2015
Start date
Oct 23, 2015
Primary completion
Mar 5, 2016
Completion
Mar 5, 2016
Last update
Nov 5, 2024

Study contacts

Medical Monitor
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion